DHA ( DrugBank: - )

---

8 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	1
46	悪性関節リウマチ	2
48	原発性抗リン脂質抗体症候群	1
49	全身性エリテマトーデス	2
94	原発性硬化性胆管炎	1
113	筋ジストロフィー	1
299	嚢胞性線維症	5
301	黄斑ジストロフィー	2

6. パーキンソン病

---

臨床試験数 : 2,298 /  薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01563913 (ClinicalTrials.gov)	October 2012	16/3/2012	Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids	Reducing Dyskinesia in Parkinson Disease With Omega-3 Fatty Acids	Parkinson's Disease	Drug: Docosahexaenoic Acid (DHA);Drug: Placebo	VA Office of Research and Development	Oregon Health and Science University	Completed	21 Years	99 Years	All	33	Phase 1	United States

46. 悪性関節リウマチ

---

臨床試験数 : 4,325 /  薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05078502 (ClinicalTrials.gov)	June 1, 2021	4/10/2021	Role of Vitamin D3 Supplementation With Conventional Synthetic Disease Modifying Antirheumatic Drugs(csDMARD) in Rheumatoid Arthritis Patients	Role of Vitamin D3 Supplementation With Conventional Synthetic Disease Modifying Antirheumatic Drugs (csDMARD) in Rheumatoid Arthritis Patients: Randomized Double-blind Placebo Controlled Trial	Rheumatoid Arthritis	Dietary Supplement: Vitamin D3	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	NULL	Completed	18 Years	70 Years	All	58	N/A	Bangladesh
2	NCT01274910 (ClinicalTrials.gov)	January 2011	4/1/2011	Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial	Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial	Rheumatoid Arthritis	Dietary Supplement: EPAX 6000 EE 1000mg (0.6 gr DHA+EPA);Dietary Supplement: Capsules (Placebo)	Rabin Medical Center	NULL	Recruiting	50 Years	80 Years	Both	60	N/A	Israel

48. 原発性抗リン脂質抗体症候群

---

臨床試験数 : 4 /  薬物数 : 5 - (DrugBank : 3) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01956188 (ClinicalTrials.gov)	May 2014	25/9/2013	Omega 3 in LES and APS	Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome	Systemic Lupus Erythematosus;Primary Antiphospholipid Syndrome	Dietary Supplement: EPA and DHA supplementation;Dietary Supplement: Placebo	University of Sao Paulo	NULL	Active, not recruiting	20 Years	45 Years	Female	22	N/A	Brazil

49. 全身性エリテマトーデス

---

臨床試験数 : 946 /  薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03396393 (ClinicalTrials.gov)	March 2018	4/1/2018	Exploratory Study of DHA in Systemic Lupus Erythematosus Patients	A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics and Efficacy of Dihydroartemisinin Tablets in Patients With Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: Dihydroartemisinin tablet;Drug: Placebo tablet	Kunming Pharmaceuticals, Inc.	NULL	Not yet recruiting	18 Years	65 Years	All	120	Phase 2	NULL
2	NCT01956188 (ClinicalTrials.gov)	May 2014	25/9/2013	Omega 3 in LES and APS	Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome	Systemic Lupus Erythematosus;Primary Antiphospholipid Syndrome	Dietary Supplement: EPA and DHA supplementation;Dietary Supplement: Placebo	University of Sao Paulo	NULL	Active, not recruiting	20 Years	45 Years	Female	22	N/A	Brazil

94. 原発性硬化性胆管炎

---

臨床試験数 : 142 /  薬物数 : 113 - (DrugBank : 37) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00325013 (ClinicalTrials.gov)	December 2005	10/5/2006	Evaluation of DHA for the Treatment of PSC	Evaluation of Docosahexaenoic Acid (DHA) for the Treatment of Primary Sclerosing Cholangitis (PSC)	Primary Sclerosing Cholangitis;Colitis	Drug: Docosahexaenoic Acid (DHA)	Beth Israel Deaconess Medical Center	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	18 Years	80 Years	Both	10	Phase 1	United States

113. 筋ジストロフィー

---

臨床試験数 : 622 /  薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01826422 (ClinicalTrials.gov)	March 2013	4/4/2013	Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients	Effect of Eicosapentaenoic Fatty Acid (EPA) and Docosahexaenoic Fatty Acids (DHA) Supplementation on the Inflammation State and Metabolic Disorders in Patients With Duchenne Muscular Dystrophy or Becker Muscular Dystrophy	Muscular Dystrophy, Duchenne	Dietary Supplement: EPA and DHA;Dietary Supplement: Placebo Comparator	Coordinación de Investigación en Salud, Mexico	Instituto Nacional de Rehabilitacion	Completed	6 Years	18 Years	Male	40	N/A	Mexico

299. 嚢胞性線維症

---

臨床試験数 : 1,696 /  薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02518672 (ClinicalTrials.gov)	October 2015	3/8/2015	Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC)	Role of DHA Monoglyceride (MAG-DHA) in the Resolution of Pulmonary Inflammation of Patients With Cystic Fibrosis.	Cystic Fibrosis	Dietary Supplement: MAG-DHA;Dietary Supplement: Placebo	SCF Pharma	Centre de recherche du Centre hospitalier universitaire de Sherbrooke;Solutex (Spain)	Terminated	18 Years	N/A	All	11	Phase 2	Canada
2	NCT02128984 (ClinicalTrials.gov)	January 2012	28/3/2014	Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children	Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children	Cystic Fibrosis;Failure to Thrive;Malnutrition	Dietary Supplement: Symbiotic Formula with DHA and antioxidants;Dietary Supplement: Standard Formula	Laboratorios Ordesa	Quantum Experimental;Peruvian Clinical Research	Completed	1 Year	N/A	All	109	N/A	Peru;Spain
3	EUCTR2010-020516-11-IT (EUCTR)	16/09/2010	28/09/2010	EXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - ND	EXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - ND	CYSTIC FIBROSIS AND PANCREATIC INSUFFICIENCY MedDRA version: 9.1;Level: PT;Classification code 10033628 MedDRA version: 9.1;Classification code 10011762	Trade Name: PREFOLIC*30CPR GASTROR 15MG INN or Proposed INN: Detoxifying agents for antineoplastic treatment Trade Name: INDUSIL*OS GTT FL 30MG+FL 15ML INN or Proposed INN: Cobamamide	AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
4	NCT00221546 (ClinicalTrials.gov)	September 2007	12/9/2005	Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis	Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: Giving DHA-rich supplement	University Hospital, Ghent	Belgian Society against Cystic Fibrosis	Completed	6 Years	N/A	Both	17	Phase 2	Belgium
5	NCT00530244 (ClinicalTrials.gov)	March 2003	13/9/2007	Use of Formula Fortified With DHA in Infants With Cystic Fibrosis	The Effect of Formula Fortified With Docosahexaenoic Acid (DHA) on Infants With Cystic Fibrosis (CF)	Cystic Fibrosis	Dietary Supplement: Docosahexaenoic acid (DHA);Dietary Supplement: Standard formula (Enfamil)	University of Massachusetts, Worcester	Cystic Fibrosis Foundation	Completed	N/A	56 Days	All	76	N/A	United States

先頭へ

301. 黄斑ジストロフィー

---

臨床試験数 : 45 /  薬物数 : 46 - (DrugBank : 12) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00420602 (ClinicalTrials.gov)	September 21, 2007	10/1/2007	DHA Supplementation in Patients With STGD3	Clinical Interventions Against Stargardt Macular Dystrophy: DHA Supplementation in Patients With STGD3	Dominantly Inherited Stargardt's Disease (STGD3)	Dietary Supplement: Over the counter DHA/EPA dietary supplementation	University of Utah	NULL	Completed	18 Years	105 Years	All	11	N/A	United States
2	NCT00060749 (ClinicalTrials.gov)	May 5, 2003	9/5/2003	Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy	Investigation of the Effect of Dietary Docosahexaenoic Acid (DHA) Supplementation on Macular Function in Subjects With Autosomal Dominant Stargardt-Like and Autosomal Recessive Stargardt Macular Dystrophy	Macular Degeneration	Drug: Docosahexaenoic Acid (DHA) Dietary Supplement	National Eye Institute (NEI)	NULL	Completed	N/A	N/A	All	22	Phase 1	United States

先頭へ